A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05864144

Public ClinicalTrials.gov record NCT05864144. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

Study identification

NCT ID: NCT05864144
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Sensei Biotherapeutics, Inc.; Industry
Enrollment: 98 participants

Conditions and interventions

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 30, 2023
Primary completion: May 31, 2027
Completion: May 31, 2027
Last update posted: Aug 14, 2025

2023 – 2027

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
UCLA Hematology/Oncology	Los Angeles	California	90095	—
University of Colorado Cancer Center - Anschutz Medical	Aurora	Colorado	80045	—
Norton Healthcare	Louisville	Kentucky	40202	—
Henry Ford Cancer	Detroit	Michigan	48202	—
Icahn School of Medicine at Mt. Sinai	New York	New York	10029	—
University of Pennsylvania, Perelman Center for Advanced Medicine	Philadelphia	Pennsylvania	19104	—
Sanford Cancer Center	Sioux Falls	South Dakota	57104	—
NEXT Oncology Dallas	Irving	Texas	75039	—
South Texas Accelerated Research Therapeutics (START) San Antonio	San Antonio	Texas	78229	—
START Mountain Region	West Valley City	Utah	84119	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05864144, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 14, 2025 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05864144 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →